“The market opportunity in the brachytherapy industry is an area we have been interested in for several years,” said Edward Brett, partner at Elysian. “We are delighted to be able to work with chairman Malcolm Hughes and managing director Saheed Rashid and the Accelyon team on this exciting opportunity. Brachytherapy has long been under-valued as an effective and cost efficient treatment for prostate cancer and we hope to raise that profile and help the team create a really world class business”
The investment thesis is focused solely on taking brachytherapy market share in the UK, Ireland, Australia and New Zealand, from which the business has the potential to deliver highly attractive returns well within the investment period, Elysian said. Subsequent phases will be rolled out internationally as the business establishes its reputation.
The investment in Accelyon represents Elysian’s seventh investment from its Elysian Capital I fund, and the second completed in this year following the acquisition of AXIS Well Technology in May 2013.
Copyright © 2013 AltAssets